US20040138154A1 - Solid surface for biomolecule delivery and high-throughput assay - Google Patents
Solid surface for biomolecule delivery and high-throughput assay Download PDFInfo
- Publication number
- US20040138154A1 US20040138154A1 US10/341,059 US34105903A US2004138154A1 US 20040138154 A1 US20040138154 A1 US 20040138154A1 US 34105903 A US34105903 A US 34105903A US 2004138154 A1 US2004138154 A1 US 2004138154A1
- Authority
- US
- United States
- Prior art keywords
- cells
- transfection
- lipid
- reagent
- biomolecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Definitions
- the present invention is related to a method for introducing biomolecules, such as nucleic acids, into cells by culturing cells on a solid surface which is coated with a transfection reagents and biomolecules for routine transfection assays and high-throughput transfection assays.
- the present invention is also related to method of use and method of making the transfectable surface for such assays.
- Gene transfection methods can be used to introduce nucleic acids into cells and are useful in studying gene regulation and function. High throughput assays that can be used to screen large sets of DNAs to identify those encoding products with properties of interest are particularly useful.
- Gene transfection is the delivery and introduction of biologically functional nucleic acids into a cell, such as a eukaryotic cell, in such a way that the nucleic acid retains its function within the cell.
- Gene transfection is widely applied in studies related to gene regulation, gene function, molecular therapy, signal transduction, drug screening, and gene therapy studies. As the cloning and cataloging of genes from higher organisms continues, researchers seek to discover the function of the genes and to identify gene products with desired properties. This growing collection of gene sequences requires the development of systematic and high-throughput approaches to characterizing gene products and analyzing gene function, as well as other areas of research in cell and molecular biology.
- Non-viral gene vectors based on a gene carrier backbone, can be classified as a) lipoplexes, b) polyplexes, and c) lipopolyplexes.
- Lipoplexes are assemblies of nucleic acids with a lipidic component, which is usually cationic. Gene transfer by lipoplexes is called lipofection.
- Polyplexes are complexes of nucleic acids with cationic polymer. Lipopolyplexes comprise both a lipid and a polymer component.
- DNA complexes are further modified to contain a cell targeting or an intracellular targeting moiety and/or a membrane-destabilizing component, for example, a viral protein or peptide or a membrane-disruptive synthetic peptide.
- a membrane-destabilizing component for example, a viral protein or peptide or a membrane-disruptive synthetic peptide.
- bacteria and phages have also been described as shuttles for the transfer of nucleic acids into cells.
- non-viral transfection reagents are synthetic cationic molecules and have been reported to “coat” the nucleic acid by interaction of the cationic sites on the cation and anionic sites on the nucleic acid.
- the positively-charged DNA-cationic molecule complex interacts with the negatively charged cell membrane to facilitate the passage of the DNA through the cell membrane by non-specific endocytosis. (Schofield, Brit. Microencapsulated. Bull, 51(1):56-71 (1995)).
- the cells are seeded on cell culture devices 16 to 24 hours before transfection.
- the transfection reagent (such as a cationic polymer carrier) and DNA were usually prepared in separate tubes, and each respective solution was diluted in medium (containing no fetal bovine serum or antibiotics). The solutions were then mixed by carefully and slowing adding one solution to the other while continuously vortexing the mixture. The mixture was incubated at room temperature for 15-45 minutes to allow the transfection reagent-DNA complexes formation to remove the residues of serum and antibiotics. Prior to transfection, the cell culture medium was removed and the cells were washed with buffer. The solution containing DNA-transfection reagent complexes was added to the cells, and the cells were incubated for about 3-4 hours. The medium containing transfection reagent would then be replaced with fresh medium. The cells would finally be analyzed at one or more specific time point(s). This is obviously a time consuming procedure, particularly when the number of samples to be transfected is very large.
- a method for introducing biomolecules into eukaryotic cells comprising (a) coating a solid surface with a biomolecule delivery reagent, (b) adding the biomolecules to be introduced into the eukaryotic cells onto the solid surface, (c) seeding cells on the solid surface at a sufficient density and under appropriate conditions for introduction of the biomolecules into the eukaryotic cells.
- the surface may be selected from the group consisting of flasks, dishes, multi-well plates, glass slides, and implanted devices.
- the biomolecule delivery reagent or transfection reagent may be selected from the group consisting of polymers, lipids, lipid-polymers and/or their combinations and/or their derivatives containing a cell-targeting or an intracellular targeting moiety and/or a membrane-destabilizing component and one or more delivery enhancers.
- the biomolecule delivery reagent can be affixed on the surface by evenly spreading the reagent on the surface or spotting said biomolecule delivery reagent in discrete areas of the surface.
- the solid surface coated with a biomolecule delivery reagent may further comprise a matrix reagent selected from the group consisting of proteins, peptides, polysaccharides, and polymers.
- the protein may be selected from gelatin, bovine serum albumin, and extracellular matrix components such as, but not limited to collagen, laminin, and fibronectin.
- the polymer may be selected from hydrogels, biodegradable polymers, and biocompatible materials.
- a solid surface is coated with a biomolecule delivery reagent which further comprises a cell culture reagent selected from the group consisting of cytoreductive reagents, cell binding/attaching reagents, cell growing reagents, cell stimulating reagents, and cell inhibiting reagents.
- a cell culture reagent selected from the group consisting of cytoreductive reagents, cell binding/attaching reagents, cell growing reagents, cell stimulating reagents, and cell inhibiting reagents.
- Biomolecules may be selected from nucleotides, proteins, peptides, sugars, polysaccharides, and organic compounds. Preferably the biomolecules are selected from DNA, RNA, and DNA/RNA hybrids.
- the nucleotides may be circular (plasmid), linear, or single strand oligodeoxynucleotide.
- RNA may be single stranded (ribozyme) or double stranded (siRNA).
- Solid surfaces used according to methods described herein may be selected from, but not limited to, a slide or a multi-well plate.
- Eukaryotic cells used according to embodiments of the invention may be, but are not limited to, mammalian cells.
- the mammalian cells may be dividing cells or non-dividing cells.
- the mammalian cells may be transformed cells or primary cells.
- the mammalian cells may be somatic cells or stem cells.
- the eukaryotic cells may be plant, yeast, or insect cells.
- a method of high throughput drug screening assay comprising (a) affixing a delivery reagent to a solid surface, (b) affixing biomolecules to be introduced into eukaryotic cells to said delivery reagent, (c) seeding cells on the surface bearing delivery reagent and biomolecules with sufficient density and under appropriate conditions for introduction of the biomolecules into the eukaryotic cells, and (d) detecting eukaryotic cells into which the biomolecule has been delivered.
- the biomolecules may be selected from, but not limited to, nucleotides, proteins, peptides, sugars, polysaccharides, and organic compounds.
- the nucleotides may be selected from, but not limited to, DNA, RNA, and DNA/RNA hybrid.
- the DNA may be circular (plasmid), linear, or single stranded oligodeoxynucleotide (ODN).
- the RNA may be single stranded (ribozyme) or double stranded (siRNA).
- the eukaryotic cells are preferably mammalian cells.
- the mammalian cells may be dividing cells or non-dividing cells and the cells may be transformed cells or primary cells.
- the mammalian cells may be somatic cells or stem cells.
- the eukaryotic cells may be selected from, but not limited to plant, bacterial, and insect cells. Detecting cells into which the biomolecule has been delivered may be performed by detecting the biomolecule itself, its product, its target molecule, the products catalyzed or products regulated by the biomolecule.
- FIG. 1 is a schematic of a transfection assay using transfectable cell culture devices or slides.
- FIG. 2 illustrates the effect of using a transfectable surface coated with various cationic polymers-gelatin transfection mixture on GFP reporter gene transfection in 923 cells in 96-well plate cell culture device system.
- the amount of Linear PEI, NDT-CP-B-1 and NDT-CP-1 were showed in the figure.
- the amounts of Superfect were 15, 7.5 and 3.75 ⁇ g/well, respectively.
- the ranges of GFP gene transfection efficiency are approximately 30-35%, and NDT-CP-1 showed the highest efficiency.
- FIG. 3 illustrates the effect of using a transfectable surface coated with various cationic polymers-gelatin transfection mixture on luciferase reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the amounts of Linear PEI, NDT-CP-B-1 and NDT-CP-1 were 8, 4, 2, and 1 ⁇ g/well, respectively.
- the amounts of Superfect were 15, 7.5 and 3.75 ⁇ g/well.
- the luciferase activities of all samples were higher than 5 ⁇ 10 7 RLU/mg protein.
- FIG. 4 illustrates the effect of using a transfectable surface coated with various cationic lipid-polymer-gelatin transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the amount of lipid-polymer was shown as 8, 4, and 2 ⁇ g/well.
- the GFP transfection efficiency could reach 20-25% in tested lipid-polymer transfection reagents.
- FIG. 5 illustrates the effect of using a transfectable surface coated with various cationic lipid-polymer-gelatin transfection mixture on luciferase reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the luciferase activity of NDT-LP-2 could reach higher than 10 6 RLU/mg protein in a lipid-polymers-gelatin transfection mixture system.
- FIG. 6 illustrates the effect of using a transfectable surface coated with cationic lipid-gelatin transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the transfection efficiency mediated by lipofectamine2000-gelatin transfection mixture in a 96-well-plate system could reach up to 30%.
- FIG. 7 illustrates the effect of using a transfectable surface coated with cationic lipid-gelatin transfection mixture on luciferase reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the luciferase activity of lipofectamine 2000 could reach up to near 10 7 RLU/mg proteins in lipid-gelatin transfection mixture system.
- FIG. 8 illustrates the effect of using a transfectable surface coated with cationic polymer-laminin transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the amounts of NDT-CP-1 and NDT-CP-B-1 are shown in the figure.
- the amounts of Superfect were 15 and 7.5 ⁇ g/ well respectively.
- the GFP transfection efficiency mediated by cationic polymer-laminin system could reach up to 50%.
- FIG. 9 illustrates the effect of using a transfectable surface coated with cationic polymer-laminin transfection mixture on luciferase reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the amount of NDT-CP-1 and NDT-CP-B-1 are shown in the figure.
- the amounts of Superfect were 15 and 7.5 and 3.75 ⁇ g/well respectively.
- the luciferase activity of cationic polymer-laminin system could reach up to 10 8 RLU/mg protein.
- FIG. 10 illustrates the effect of using a transfectable surface coated with cationic lipid-polymer-laminin transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the amount of lipid-polymer was shown as 8, 4, and 2 ⁇ g/well.
- the GFP transfection efficiency mediated by lipid-polymer-laminin transfection mixture system could reach up to 45%.
- FIG. 11 illustrates the effect of using a transfectable surface coated with cationic lipid-polymer-laminin transfection mixture on luciferase reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the amount of lipid-polymer is shown in the figure.
- the luciferase activity of lipid polymer-laminin transfection mixture system could reach up to 8 ⁇ 10 7 RLU/mg of protein.
- FIG. 12 illustrates the effect of using a transfectable surface coated with cationic lipid-laminin transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the transfection efficiency mediated by lipofectamine-laminin transfection mixture system could reach up to 45%.
- FIG. 13 illustrates the effect of using a transfectable surface coated with cationic lipid-laminin transfection mixture on luciferase reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the luciferase activity of lipofectamine 2000-laminin transfection mixture system could reach up to 1.5 ⁇ 10 7 RLU/mg protein.
- FIG. 14 illustrates the effect of using a transfectable surface coated with cationic polymer-collagen transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the amounts of NDT-CP-1 and NDT-CP-B-1 is shown in the figure.
- the amounts of Superfect were 15 and 7.5 ⁇ g/well respectively.
- the GFP transfection efficiency mediated by cationic polymer-collagen transfection mixture system could reach up to 40%.
- FIG. 15 illustrates the effect of using a transfectable surface coated with cationic lipid-polymer-collagen transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the amount of lipid-polymer is shown as 8, 4, and 2 ⁇ g/well.
- the transfection efficiency mediated by cationic lipid-polymer-collagen transfection mixture system could reach up to 35%.
- FIG. 16 illustrates the effect of using a transfectable surface coated with cationic lipid-collagen transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the transfection efficiency mediated by cationic lipid-collagen transfection mixture system could reach up to 35%, similar to those mediated by lipofectamine 2000-gelatin transfection mixture system.
- FIG. 17 illustrates the effect of using a transfectable surface coated with cationic polymer-gelatin-laminin transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the amounts of NDT-CP-1 and NDT-CP-B-1 are shown in the figure.
- the amounts of Superfect were 15 and 7.5 ⁇ g/well respectively.
- the GFP transfection efficiency mediated by the cationic polymer-gelatin-laminin transfection mixture system could reach up to 42%.
- FIG. 18 illustrates the effect of using a transfectable surface coated with cationic lipid-polymer-gelatin-laminin transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the amount of lipid-polymer is shown as 8, 4, and 2 ug/well.
- the GFP transfection efficiency mediated by the cationic lipid-polymer-gelatin-laminin transfection mixture system could reach up to 40%.
- FIG. 19 illustrates the effect of using a transfectable surface coated with cationic lipid-gelatin-laminin transfection mixture on GFP reporter gene transfection in 923 cells in a 96-well plate cell culture device system.
- the transfection efficiency mediated by cationic lipid-gelatin-laminin transfection mixture system could reach up to 30%.
- FIG. 20 illustrates a GFP reporter gene transfection assay in 923 cells with a transfectable glass slide system spotted with cationic polymer (NDT-CP-1)-gelatin or cationic lipid (lipofectamine2000)-gelatin transfection mixture.
- the transfectable slide was submerged in a GFP plasmid solution. Although the whole slide was covered with GFP plasmid solution, only the cells that are on the spot where the transfection mixtures were applied exhibited a GFP signal. This indicates that the transfection reagents were well affixed on the glass slide without diffusion.
- FIG. 21 illustrates a GFP reporter gene transfection assay in 923 cells with a transfectable glass slide system coated with cationic polymer (NDT-CP-1)-gelatin or cationic lipid (lipofectamine2000)-gelatin transfection mixture.
- the transfectable slide was loaded with GFP plasmid DNA by spotting 1-4 ⁇ l GFP plasmid (20 ⁇ g/ml) solution and allowing the slide to air dry. The glass slide was then put on the bottom of a six-well plate, followed by seeding 293 cells. The GFP signal was analyzed by fluorescent microscope.
- FIG. 22 illustrates a GFP reporter gene transfection assay in 923 cells with a transfectable glass slide system spotted with cationic polymer (NDT-CP-1)-laminin or cationic lipid (lipofectamine2000)-laminin transfection mixture.
- the transfectable slide was submerged in GFP plasmid solution. Although the whole slide was covered with GFP plasmid solution, only the cells that are on the spot where transfection mixtures were applied exhibited a GFP signal. This indicates that the transfection reagents were well affixed on the glass slide without diffusion.
- FIG. 23 illustrates a GFP reporter gene transfection assay in 923 cells with a transfectable glass slide system coated with cationic polymer (NDT-CP-1)-laminin or cationic lipid (lipofectamine2000)-laminin transfection mixture.
- the transfectable slide was loaded with GFP plasmid DNA by spotting 1-4 ⁇ l GFP plasmid (20 ⁇ g/ml) solution and allowing the slide to air dry. The glass slide was then put on the bottom of a six-well plate, followed by seeding 293 cells. The GFP signal was analyzed by fluorescent microscope.
- FIG. 24 illustrates the effect of using transfection reagent-laminin mixtures on antisense ODN transfection to Hela 705 Luc cells in a 96-well cell culture device.
- the results showed that transfectable surface composed of cationic polymer-laminin transfection mixture, lipid-polymer-laminin mixture, or lipid-laminin transfection mixture systems showed significant blocking of the target RNA, which suggested that not only plasmid, but also oligonucleotide could be successfully delivered into mammalian cells by this strategy.
- FIG. 25 illustrates the effect of using transfection reagent-laminin mixtures on siRNA delivery to 293 cells in a 96-well cell culture device.
- transfectable surfaces composed of cationic polymer-laminin transfection mixture, lipid-polymer-laminin mixture, or lipid-laminin transfection mixture systems showed significant blocking of the target RNA, which suggested that not only plasmid, but also siRNA could be successfully delivered into mammalian cells by this strategy.
- FIG. 26 illustrates typical results of Tat peptide signal in HeLa cells. hn FIG. 26A, Tat was coated in solid surface with gelatin matrix. FIG. 26B shows the non-Tat control. About 60-80% cells showed FITC signal in the Tat-coated group. This indicates that not only nucleic acid, but also peptides, can be delivered into cells according to embodiments of the present invention.
- FIG. 27 illustrates the effect of a targeting molecule (transferring) on cationic polymer (PLL)-laminin transfection mixture mediated gene transfer in HepG2 cells with transfectable surface technology in a 96-well cell culture device system.
- the results indicate that introduction of targeting molecules (transferring) in PLL-laminin based transfectable surface systems could significantly enhance transfection efficiency.
- FIG. 28 illustrates the effect of membrane disturbing peptide (VSVG peptide) on cationic polymer (PLL)-laminin transfection mixture mediated gene transfer in 293 cells with transfectable surface technology in a 96-well cell culture device system.
- the results indicate that introduction of membrane disturbing peptide (VSVG peptide) in PLL-laminin based transfectable surface systems could significantly enhance transfection efficiency.
- FIG. 29 illustrate the effect of using transfection reagent-laminin mixtures in GFP reporter gene delivery to HUV-EC cells in a 96-well cell culture device.
- the GFP transfection efficiency of NDT-CP-1 was about 20%, and the efficiency of Superfect was about 15%.
- the lipofectamine showed very low transfection efficiency ( ⁇ 1.0%). It indicated that not only transformed cell lines, such as 293, HeLa, HepG2 could be transfected, but also primary cells could be transfected by cationic polymer-laminin transfection mixture systems.
- FIG. 30 illustrates the effect of transfection reagent-laminin mixtures on luciferase reporter gene delivery to HUV-EC cells in a 96-well cell culture device.
- the transfection efficiency of NDT-CP-1 and Superfect transfection efficiency were 1.26 ⁇ 10 7 and 8.26 ⁇ 10 6 RLU/mg protein respectively.
- Lipofectamine 2000 showed lower efficiency compared to the cationic polymer-laminin mixture system. This further confirmed that primary cells could be transfected with different gene according to embodiments of the present invention.
- FIG. 31 illustrates the cell survival fraction of 293 cells after transfection in a 96 well plate coated with transfection reagent-gelatin. All samples showed a high survival fraction (>65%). It indicates that the cytotoxicity of transfection reagents used according to methods described herein are acceptable.
- FIG. 32 illustrates the effect of introduction of cytoreductive reagents (glutamine) in a transfection reagents-laminin based transfectable surface on cytotoxicity improvement in 293 cells.
- the “Non” indicates samples without glutamine
- “G” indicates samples with glutamine.
- the results showed that glutamine (cytoreductive reagent) significantly improved transfection cytotoxicity compared to that without glutamine group, which indicated that cytoreductive reagents are excellent candidates for reducing cytotoxicity caused by transfection reagents and transfection procedures.
- FIG. 33 illustrates the effect of introduction of cell attaching reagents and cell stimulating reagent (laminin) in a transfection reagents-gelatin based transfectable surface on cytotoxicity improvement to 293 cells.
- “L” indicates samples with laminin and “Non” indicates samples without laminin.
- the results indicate that the cell attaching reagent, such as laminin, significantly improved cytotoxicity caused by transfection reagents and transfection procedures in a transfectable surface technology system.
- FIG. 34 illustrates an evaluation of shelf-life of transfectable surfaces in stability studies. The results showed that there are no significant differences in transfection performances in flash-made transfectable surfaces or that with the treatment at 37° C. for 9 days, which indicated that the shelf life of transfectable surface could be 1.5 years when stored at 4° C.
- FIG. 35 is a table illustrating the structures of NDT synthesized polymers and lipid-polymers.
- a novel transfection device and method are described herein which is simple, convenient, and efficient compared to conventional transfection assays.
- a transfection device is made according to methods described herein by affixing a transfection reagent on the solid surface of a cell culture device. By using this device, researchers need only add a nucleic acid or other biomolecule carrier system to the surface of the cell culture device. There is no need to pre-mix the DNA or biomolecule with a transfection reagent. This removes a key timing-consuming step, which is required by conventional transfection procedures.
- scientistss only require approximately 40 minutes to complete the entire transfection process for 10 samples, compared to 2 to 5 hours or more required by current methods. This is particularly favorable for high throughput transfection assays, in which hundreds of samples will be tested at a time.
- transfection device that is very easy to store, and it provides a simple method for biomolecule delivery or gene transfection in which no biomaterial/transfection reagent mixing step is required.
- the transfection procedure described herein can be finished in a short period of time, for instance approximately 40 minutes, and it provides a high throughput method for transfection or drug delivery in which large numbers of samples may be transfected at a time.
- a novel method and device for gene delivery are described herein, which overcome the common problems encountered in conventional transfection assays described above.
- Transfection reagents are simply coated onto the surface of a cell culture device, which can be easily commercialized and mass-produced.
- Cells are then seeded on the surface of the cell culture device and incubated, without changing the medium, and the cells are analyzed. Changing medium during transfection procedure is unnecessary.
- the methods described herein dramatically reduce the risk of error, by reducing the number of steps involved, thus increasing consistency and accuracy of the system.
- transfection reagents were affixed on the surface of a slide, multi-well plate, or other surface to form a transfection device.
- people need only add DNA or other biomolecule to the surface and allow the transfection reagent to form a complex with the DNA or biomolecule.
- This reaction occurs in approximately 30 minutes, then cells are seeded on the surface and incubated in suitable condition for introduction of the biomoloecule(s) into the cells.
- any suitable surface that can be used to affix the nucleic acid/biomolecule-containing mixture to its surface can be used.
- the surface can be glass, plastics (such as polytetrafluoroethylene, polyvinylidenedifluoride, polystyrene, polycarbonate, polypropylene), silicon, metal, (such as gold), membranes (such as nitrocellulose, methylcellulose, PTFE or cellulose), paper, biomaterials (such as protein, gelatin, agar), tissues (such as skin, endothelial tissue, bone, cartilage), minerals (such as hydroxylapatite, graphite).
- the surfaces may be slides (glass or poly-L-lysine coated slides) or wells of a multi-well plate.
- the transfection reagents are fixed on the surface and dried, and then a nucleic acid of interest or a nucleic acid to be introduced into cells, a protein, peptide, or small molecule drug is introduced.
- the slide is incubated at room temperature for 30 minutes to form biomolecule/transfection reagent complexes on the surface of the transfection device.
- the biomolecule/transfection reagent complexes create a medium for use in high throughput microarrays, which can be used to study hundreds to thousands of nucleic acids, proteins, peptides and other small molecular drugs at same time.
- the transfection reagents or drug delivery reagents can be affixed on the surface of the transfection device in discrete, defined regions to form a microarray of transfection reagents or drug delivery reagents.
- molecules, such as nucleic acids, which are to be introduced into cells are spread on the surface of the transfection device along with a transfection or delivery reagent.
- This method can be used in screening transfection reagents or other delivery reagents from thousands of compounds. The results of such a screening method can be examined through computer analysis.
- one of more well of a multi-well plate may be coated with a transfection or drug delivery reagent.
- Plates commonly used in transfection and drug screening are 96-well and 384-well plates.
- the transfection or biomolecule delivery reagent can be evenly applied to the bottom of plate.
- Hundreds of nucleic acids, proteins, peptides or other biomolecules are then added into the well(s) by, for instance, a multichannel pipette or automated machine. Results of transfection are then determined by using a microplate reader. This is a very convenient method of analyzing the transfected cells, because microplate readers are commonly used in most biomedical laboratories.
- the multi-well plate coated with transfection or biomolecule delivery reagent can be widely used in most laboratories to study gene regulation, gene function, molecular therapy, and signal transduction, as well as drug screening. Also, if different kinds of transfection reagents are coated on the different wells of multi-well plates, the plates can be used to screen many transfection or delivery reagents relatively efficiently. Recently, 1,536 and 3,456 well plates have been developed, which may also be used according to the methods described herein.
- the transfection reagent or delivery reagent are preferably cationic compounds which can introduce biomolecules, such as nucleic acids, proteins, peptides, sugars, polysaccharides, organic compounds, and other biomolecules into cells.
- Preferred embodiments use cationic oligomers, such as low molecular weight polyethyleneimine (PEI), low molecular weight poly(L-lysine) (PLL), low molecular weight chitosan, or low molecular weight dendrimers.
- reagents can be classified as: lipids, polymers, lipid-polymers and/or their combinations and/or their derivatives, which contain a cell-targeting or an intracellular-targeting moiety and/or a membrane-destabilizing component, as well as delivery enhancers.
- the delivery reagent can be mixed with a matrix, such as proteins, peptides, polysaccharides, or other polymers.
- the protein can be gelatin, collagen, bovine serum albumin or any other protein that can be used in affixing proteins to a surface.
- the polymers can be hydrogels, copolymers, non-degradable or biodegradable polymers and biocompatible materials.
- the polysaccharide can be any compound that can form a membrane and coat the delivery reagent, such chitosan.
- reagents such as cytotoxicity reductive reagents, cell binding reagents, cell growing reagents, cell stimulating reagents or cell inhibiting reagents and the compounds for culturing specific cells, can be also affixed to the transfection device along with the transfection or delivery reagent.
- a gelatin-transfection reagent mixture comprising transfection reagent (e.g., lipid, polymer, lipid-polymer or membrane destabilizing peptide) and gelatin that is present in an appropriate solvent, such as water or double deionized water, may be affixed to the transfection device.
- transfection reagent e.g., lipid, polymer, lipid-polymer or membrane destabilizing peptide
- an appropriate solvent such as water or double deionized water
- a cell culture reagent may also be present in the gelatin-transfection reagent mixture.
- the mixture is evenly spread onto a surface, such as a slide and multi-well plate, thus producing a transfection surface bearing the gelatin-transfection reagent mixture.
- different transfection reagent-gelatin mixtures may also be spotted on discrete regions on the surface of the transfection device.
- the resulting product is allowed to dry completely under suitable conditions such that the gelatin-transfection reagent mixture is affixed at the site of application of the mixture.
- the resulting product to can be dried at specific temperatures or humidity or in a vacuum-dessicator.
- the concentration of transfection reagent present in the mixture depends on the transfection efficiency and cytotoxicity of the reagent. Typically there is a balance between transfection efficiency and cytotoxicity. At concentrations in which a transfection reagent is most efficient, while keeping cytotoxicity at an acceptable level, the concentration of transfection reagent is at the optimal level.
- the concentration of transfection reagent will generally be in the range of about 1.0 ⁇ g/ml to about 1000 ⁇ g/ml. In preferred embodiments, the concentration is from about 40 ⁇ g/ml to about 600 ⁇ g/ml.
- the concentration of gelatin or another matrix depends on the experiment or assay to be performed, but the concentration will generally be in the range of 0.01% to 0.5% of the transfection reagent. According to embodiments shown in the examples the gelatin concentration is about 0.2% of the transfection reagent.
- the molecules to be introduced into cells can be nucleic acids, proteins, peptides, peptide nucleic acid (PNA) and other biomolecules.
- the nucleic acid can be DNA, RNA and DNA/hybrid, etc.
- the vector can be of any type, such as a plasmid (e.g. example, pCMV-GFP, pCMV-luc) or viral-based vector(e.g. pLXSN).
- the DNA can also be linear fragment with a promoter sequence (such CMV promoter) at the 5′ end of the cDNA to be expressed and a poly A site at the 3′ end.
- the DNA is the single strand oligodeoxynucleotide (ODN), for example antisense ODN, it can be introduced into cells to regulate target gene expression.
- ODN single strand oligodeoxynucleotide
- the nucleic acid may be single stranded (antisense RNA and ribozyme) or double stranded (RNA interference, SiRNA).
- SiRNA RNA interference
- the RNA is modified in order to increase the stability of RNA and improve its function in down regulation of gene expression.
- PNA peptide nucleic acid
- the nucleic acid backbone is replaced by peptide, which makes the molecule more stable.
- the methods described herein can be used to introduce proteins, peptides and other molecules into cells for various purposes, for example molecular therapy, protein function studies, or molecule mechanism studies.
- the biomolecules are added into the transfction device, which is coated with transfection or delivery reagent(s), to form biomolecule/delivery reagent complexes.
- the biomolecules are preferably dissolved in cell culture medium without fetal bovine serum and antibiotics, for example Dulbecco's Modified Eagles Medium (DMEM). If the transfection or delivery reagent is evenly affixed on the slide, the biomolecules can be spotted onto discrete locations on the slide. Alternatively, transfection or delivery reagents may be spotted on descrete locations on the slide, and the biomolecules can simply be added to cover the whole surface of the transfection device.
- DMEM Dulbecco's Modified Eagles Medium
- the biomolecules are simply added into different wells by multi-channel pipette, automated device, or other method.
- the resulting product (transfection device coated with transfection or delivery reagent and biomolecules) is incubated for approximately 25 minutes room temperature to form the bio-molecule/transfection reagent (or delivery reagent) complexes.
- the DNA solution will be remove to produce a surface bearing biomolecules in complex with transfection reagent.
- the biomolecules solution can be kept on the surface.
- Sequently, cells in an appropriate medium and appropriate density are plated onto the surface.
- the resulting product (a surface bearing biomolecules and plated cells) is maintained under conditions that result in entry of the biomolecules into plated cells.
- Suitable cells for use according to the methods described herein include prokaryotes, yeast, or higher eukaryotic cells, including plant and animal cells, especially mammalian cells.
- Eukaryotic cells such as mammalian cells (e.g., human, monkey, canine, feline, bovine, or murine cells), bacterial, insect or plant cells, are plated onto the transfection device, which is coated with transfection or delivery reagent and biomolecules, in sufficient density and under appropriate conditions for introduction/entry of the biomolecule into the eukaryotic cells and either expression of the DNA or interaction of the biomolecule with cellular components.
- the cells maybe selected from hematopoietic cells, neuronal cells, pancreatic cells, hepatic cells, chondrocytes, osteocytes, or myocytes.
- the cells can be fully differentiated cells or progenitor/stem cells.
- eukaryotic cells are grown in Dulbecco's Modified Eagles Medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS) with L-glutamine and penicillin/streptomycin (pen/strep).
- DMEM Dulbecco's Modified Eagles Medium
- FBS heat-inactivated fetal bovine serum
- pen/strep penicillin/streptomycin
- the cells are incubated under optimal conditions for the cell type (e.g. 37° C., 5-10% CO 2 ).
- the culture time is dependent on the purpose of experiment. Typically, the cells are incubated for 24 to 48 hours for cells to express the target gene in the case of gene transfection experiments. In the analysis of intracellular trafficking of biomolecules in cells, minutes to several hours of incubation may be required and the cells can be observed at defined time points.
- the results of biomolecule delivery can be analyzed by different methods.
- the target gene expression level can be detected by reporter genes, such as green fluorescent protein (GFP) gene, luciferase gene, or ⁇ -galactosidase gene expression.
- GFP green fluorescent protein
- the signal of GFP can be directly observed under microscope, the activity of luciferase can be detected by a luminometer, and the blue product catalyzed by ⁇ -galactosidase can be observed under microscope or determined by a microplate reader.
- GFP green fluorescent protein
- the nucleic acid and its product, the protein, peptide, or other biomolecules delivered according to methods described herein and the target modulated by these biomolecules can be determined by various methods, such as detecting immunofluorescence or enzyme immunocytochemistry, autoradiography, or in situ hybridization. If immunofluorescence is used to detect expression of an encoded protein, a fluorescently labeled antibody that binds the target protein is used (e.g., added to the slide under conditions suitable for binding of the antibody to the protein). Cells containing the protein are then identified by detecting a fluorescent signal. If the delivered molecules can modulate gene expression, the target gene expression level can also be determined by methods such as autoradiography, in situ hybridization, and in situ PCR. However, the identification method depends on the properties of the delivered biomolecules, their expression product, the target modulated by it, and/or the final product resulting from delivery of the biomolecules.
- Branched PEI 25K polyethyleneimine of Mw 25 KDa
- Linear PEI 25K Linear PEI 25K
- Superfect(TM) Qiagen, Valencia, Calif.
- Transfection Reagent LipofectAMINETM was purchased from Life Technologies (Gaithersburg, Md.) and was used as provided by the manufacturers.
- NDT-CP-B-1 degradable
- NDT-CP-1 non-degradable
- NDT-LP-1 was lipid-polymer containing polymer and lipid structure on the same molecule. The structures of NDT polymeric transfection reagents are shown in FIG. 35.
- Gelatin powder Type B 225 Bloom (Sigma, catalog #G-9391) was dissolved in sterile MilliQ water by gently swirling the solution for 15 minutes in a 60° C. water bath. The 0.2% gelatin solution was then cooled at room temperature, and while still warm ( ⁇ 37-40° C.), the solution was filtered through a 0.45 ⁇ m cellular acetate membrane (CA). One hundred ml of solution was prepared and stored in 50 ml aliquots of the filtered gelatin solution at 4° C.
- CA 0.45 ⁇ m cellular acetate membrane
- All transfection reagents were diluted in the 0.2% gelatin solution.
- the concentration of linear PEI 25k and specially synthesized polymer samples ranged from 320.0 ⁇ g/ml to 40.0 ⁇ g/ml, and the concentration of branched PEI 25k ranged from 160.0 ⁇ g/ml to 20.0 ⁇ g/ml.
- the concentration of Superfect ranged from 600.0 to 75.0 ⁇ g/ml, and lipofectamine concentration ranged from 200.0 ⁇ g/ml to 25.0 ⁇ g/ml.
- the concentration of polymers and lipid-polymer synthesized (NDT) ranged from 320.0 ⁇ g/ml to 40.0 ⁇ /ml.
- Laminin (Sigma, catalog #L2020) was diluted in PBS to a final concentration of 40.0 ⁇ g/ml and stored at 4° C.
- All transfection reagents were diluted in the 40.0 ⁇ g/ml laminin solution.
- the concentration of linear PEI 25k and specially synthesized polymer samples ranged from 320.0 ⁇ g/ml to 40.0 ⁇ g/ml, and the concentration of branch PEI 25k ranged from 160.0 ⁇ g/ml to 20.0 ⁇ g/ml.
- the concentration of Superfect ranged from 600.0 to 75.0 ⁇ g/ml, and lipofectamine concentration ranged from 200.0 ⁇ g/ml to 25.0 ⁇ g/ml.
- the concentration of polymers and lipid-polymer synthesized (NDT) ranged from 320.0 ⁇ g/ml to 40.0 ⁇ g/ml.
- Collagen (Sigma, catalog #C8919) was diluted in PBS to a final concentration of 120.0 ⁇ g/ml and stored at 4° C.
- All transfection reagents were diluted in the 120.0 ⁇ g/ml of collagen solution.
- the concentration of linear PEI 25k and specially synthesized polymer samples ranged from 320.0 ⁇ g/ml to 40.0 ⁇ g/ml, and the concentration of branched PEI 25k ranged from 160.0 ⁇ g/ml to 20.0 ⁇ g/ml.
- the concentration of Superfect ranged from 600.0 to 75.0 ⁇ g/ml, and lipofectamine concentration ranged from 200.0 ⁇ g/ml to 25.0 ⁇ g/ml.
- the concentration of polymers and lipid-polymer synthesized (NDT) ranged from 320.0 ⁇ g/ml to 40.0 ⁇ g/ml.
- Laminin (Sigma, catalog #L2020) was diluted in 0.2% gelatin to a final concentration of 40.0 ⁇ g/ml and stored at 4° C.
- All transfection reagents were diluted in the 40.0 ⁇ g/ml laminin/0.2% gelatin solution.
- the concentration of linear PEI 25k and specially synthesized polymer samples ranged from 320.0 ⁇ g/ml to 40.0 ⁇ g/ml, and the concentration of branch PEI 25k ranged from 160.0 ⁇ g/ml to 20.0 ⁇ g/ml.
- the concentration of Superfect ranged from 600.0 to 75.0 ⁇ g/ml, and lipofectamine concentration ranged from 200.0 ⁇ g/ml to 25.0 ⁇ g/ml.
- the concentration of polymers and lipid-polymer synthesized (NDT) ranged from 320.0 ⁇ g/ml to 40.0 ⁇ g/ml.
- the plasmids pCMV-GFP and pCMV-luc were constructed according to standard DNA recombinant protocols.
- the expression of green fluorescent protein (GFP) and firefly luciferase gene cDNA was controlled by the human cytomegalovirus (CMV) promoter, and the transcripts were stabilized by a gene expression enhancer, chicken ⁇ -globulin intron.
- the plasmids were amplified in DH5 ⁇ E. coli and purified with Qiagen Plasmid Max Preparation Kit according to the manufacturer's instruction.
- the quantity and quality of the purified plasmid DNA was assessed by spectrophotometric analysis at 260 and 280 nm, as well as by electrophoresis in 0.8% agarose gel. Purified plasmid DNA was dissolved in sterile ddH 2 O and stored at ⁇ 20° C.
- pCMV-GFP or pCMV-luc plasmid was diluted in DMEM to a final concentration of 10 ⁇ g/ml. Thirty (30) ⁇ l DNA solution was added to the transfectable surface of 96-well plate or glass slide, and incubated at room temperature for 20-30 min.
- Luciferase 705 reporter gene system was developed by Dr. Kole in University of Northern Carolina (Kang S H et al. Biochemistry 1998;37(18):6235-9). In this system, human ⁇ -globin with mutation at 705 was inserted into the sequence between luciferase cDNA. This plasmid was introduced into HeLa cell for stable gene expression; the cell line was termed as HeLa luc705. Usually the cells exhibit low luciferase activity, because the gene products (luciferases) with wrong splicing exhibit no activities. However, the antisense oligonucleotide binding to 705 sequence will block the wrong splicing site and produce luciferase protein with biological activity. Luciferase 705 is used as functional model for evaluation of the efficiency of antisense oligonucleotide delivery. Higher luciferase activity indicates higher efficiency of antisense delivery.
- siRNA is a double stranded RNA fragment with 21 to 25 bp, which can bind and destroy target mRNA and lead to down regulation of gene expression levels.
- the luciferase plasmid and siRNA synthetic cassette which targets luciferase gene were prepared in opti MEM and were added into the transfectable plate described previously and incubated for 25 min.
- the amounts of luciferase plasmids were 0.5 ⁇ g/well and siRNA synthetic cassettes were about 0.5 ⁇ g/ well (FIG. 25).
- Biotin labeled Tat peptide of various concentrations were prepared with 0.2% gelatin solution and coated on a 96 well plate, respectively. The plate was dried by sitting in a cell culture hood for several hours. 1.5 ⁇ 10 4 HeLa cells/well were seeded on the plate coated with peptide and incubated at 37° C. for 4h. The cells were fixed with 0.2% glutaraldehyde/PBS for 5 min followed by treatment with 10% methanol. After being blocked with 10% serum at 37° C. for 30 min, the cells were incubated with streptavidin-FITC at 37° C. for 30 min. The cells were washed with PBS and the fluorescent signal was observed under a fluorescent microscope.
- the biotin-conjugated peptide can specifically bind to strreptavidin-FITC and lead to peptides be able to produce fluorescent signals.
- the increased FITC signal in cells indicates that more peptides were transported into the cells (FIG. 26).
- Transferrin can be absorbed by liver cells in a transferrin receptor mediated endocytosis pathway. Transferrin has been successfully reported as cell targeting molecular that could improve gene delivery efficiency in liver cells (Wagner E, Ogris M, Zauner W. Adv Drug Deliv Rev 1998; 30(1-3):97-113).
- VSVG is a viral envelope protein with membrane-destabilizing properties resulting in membrane fusion and disruption of the membranes of the cell.
- VSVG has been used as a gene transfection enhancer which can dramatically increase the cationic polymer (PLL) mediated gene transfection.
- PLL cationic polymer
- VSVG peptide and poly-L-lysine were diluted in 40.0 ⁇ g/ml laminin.
- the concentration of VSVG peptide was 1.0 mg/ml, and the concentration of PLL ranged from 640 ⁇ g/ml to 160.0 ⁇ g/ml.
- PLL was diluted in laminin solution at same concentration. 25 ⁇ l of the PLL or PLL+VSVG peptide solution was added into 96 well plate and let it air dry. The amount of PLL was 16.0, 8.0 and 4.0 ⁇ g/well respectively (FIG. 28).
- Glutamine is a cytoreductive reagent which can protect cells against ammonia-induced cytotoxicity (Nakamura E and Hagen S J. Am J Physiol Gastointest liver Physiol 283 G1264-1275, (2002)). Since almost all cationic polymers or cationic lipids contain amine groups, the addition of glutamine into the transfection mixture for transfectable surface preparation plays a role in protection against the cytotoxicity of transfection.
- Glutamine (100 mmol/L) and different transfection reagents were diluted in 0.2% gelatin solution, and 25 ⁇ l of the solution containing Glutamine/transfection reagent/gelatin was added into a 96 well plate and allowed to air dry. Then 25 ⁇ l GFP plasmid solution in opti MEM (20.0 ⁇ g/ml) was added into each well and incubated at room temperature for 25 min. The dried plate was ready for use (FIG. 32).
- Laminin is a matrix for support cell growth and differentiation.
- Laminin is a commonly used cell attaching reagent.
- 0.2% gelatin or 0.2% gelatin and 40.0 ⁇ g/ml laminin mixture was used for diluting transaection reagents NDT-CP-B-1, NDT-CP-1, NDT-LP-1 NDT-LP-2, Superfect and lipofectamine 2000, and 25 ⁇ l solution was added into 96 well plate.
- the amounts of NDT polymers used in each well were 8, 4 or 2 ⁇ g, respectively, the amounts of Superfect were 15, 7.5 and 3.8 ⁇ g/well respectively, and the amounts of lipofectamine 2000 were 2.5, 1.25 and 0.63 ⁇ g/well respectively.
- HEK 293T cells was maintained in DMEM (Gibco) containing 10% fetal bovine serum, 100 units/ml penicillin and 100 ⁇ g/ml streptomycin. In this media the cells had a doubling time of about 20 hours, and the cells were split every 3-4 days to avoid over confluency.
- HeLa 705 cell line was from Human cervical carcinoma HeLa cells after introducing firefly luciferase gene with a mutant ⁇ -globin intron (a mutation at 705 position) which results in a mutated luciferease protein due to the incorrect splicing.
- the mutated intron can be corrected by a specific antisense oligo nucleotide after it blocks the wrong splicing site (Kang S H et al. Biochemistry 1998;37(18):6235-9).
- the cell line was maintained in DMEM (Gibco) containing 10% fetal bovine serum, 100 units/ml penicillin and 100 ⁇ g/ml streptomycin. 200 ⁇ g/ml hygromycin was added into medium to maintain the luc-705 plasmid. In this media the cells had a doubling time of about 20 hours, and the cells were split every 3-4 days to avoid over confluency.
- Human liver tumor cell line HepG2 was maintained in ⁇ -MEM medium (Gibco) containing 10% fetal bovine serum, 100 units/ml penicillin and 100 ⁇ g/ml streptomycin. In this media the cells had a doubling time of about 20 hours, and the cells were split every 3-4 days to avoid over confluency.
- ⁇ -MEM medium Gibco
- Human primary endothelial cell HUV-EC cell line was grew and maintained in EBM medium (Cambrex Corp.) containing 10% fetal bovine serum, 100 units/ml penicillin and 100 ⁇ g/ml streptomycin, and different types of growth factors according to the manufacturers instructions (FIG. 29- 30 ).
- HEK 293T, HepG2 cells were diluted to a final concentration of 4-5 ⁇ 10 5 cell/well in a sterile basin, and 100 ⁇ l (4-5 ⁇ 10 4 cells) were be seeded for each well in a 96-well plate.
- the optimal concentration of HeLa 705 and HUV-EC cells were 1-2 ⁇ 10 5 cell/ml.
- Green fluorescent protein (GFP) gene was used in an initial screening. After transfection, the GFP signal in cells was observed under fluorescent microscope (Olympus, filter 520 nm). Cells were photographed using a 10 ⁇ objective. The percentage of cells with GFP signal in transfected cultures was determined from counts of three fields for optimal cationic polymer amounts.
- luciferase activity was performed using a chemiluminescent assay following the manufacturer's instructions (Luciferase Assay System; Promega, Madison, Wis., USA). Briefly, thirty hours after gene transfer, the cells were rinsed twice with PBS and then were lysed with lysis buffer (1% Triton X-100, 100 mM K 3 PO 4 , 2 mM dithiothreitol, 10% glycerol, and 2 mM EDTA pH 7.8) for 15 min at room temperature. A 10- ⁇ l aliquot of cell lysate was then mixed with 50- ⁇ l of luciferase assay reagent with an injector at room temperature in the luminometer.
- lysis buffer 1% Triton X-100, 100 mM K 3 PO 4 , 2 mM dithiothreitol, 10% glycerol, and 2 mM EDTA pH 7.8
- RLU Relative light units
- LPEI, BPEI, NDT-CP-B-1, NDT-CP-1, Superfect and lipofectamine in 0.2% gelatin were coated in 96-well plate as described previously. After air-drying, the plate was incubated at 37° C. for 9 days. The plate was then ready for use. 25 ⁇ l/well luciferase plasmid (20.0 ⁇ g/ml in optimal MEM) was added to the plates (before and after 37° C. incubation) and incubated for 25 min. 5 ⁇ 10 4 293 cells were seed in the plate and incubated at 37° C. for 48 hours. The gene transfection efficiency of the transfectable surface of the flash plate or of 37° C. incubation for 9 days was compared (FIG. 34).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/341,059 US20040138154A1 (en) | 2003-01-13 | 2003-01-13 | Solid surface for biomolecule delivery and high-throughput assay |
EP10075260A EP2253718B1 (en) | 2003-01-13 | 2003-12-04 | Solid surface for biomolecule delivery and high-throughput assay |
AU2003298863A AU2003298863B2 (en) | 2003-01-13 | 2003-12-04 | Solid surface for biomolecule delivery and high-throughput assay |
JP2004566927A JP4580764B2 (ja) | 2003-01-13 | 2003-12-04 | 生体分子送達用固体表面およびハイスループットアッセイ |
KR1020057012842A KR100863774B1 (ko) | 2003-01-13 | 2003-12-04 | 생물분자 전달용 고형 표면 및 처리효율이 높은 분석 방법 |
CN2003801086781A CN1738911B (zh) | 2003-01-13 | 2003-12-04 | 用于生物分子递送和高通量实验方法的固体表面 |
EP03796622A EP1587954B1 (en) | 2003-01-13 | 2003-12-04 | Solid surface for biomolecule delivery and high-throughput assay |
DK10075260.9T DK2253718T3 (da) | 2003-01-13 | 2003-12-04 | Fast overflade til biomolekylafgivelse og analyse med høj omsætning |
AT03796622T ATE477336T1 (de) | 2003-01-13 | 2003-12-04 | Feste oberfläche für biomolekülabgabe und assay mit hoher durchlaufleistung |
PCT/US2003/038498 WO2004065636A1 (en) | 2003-01-13 | 2003-12-04 | Solid surface for biomolecule delivery and high-throughput assay |
DE60333793T DE60333793D1 (de) | 2003-01-13 | 2003-12-04 | Feste oberfläche für biomolekülabgabe und assay mit hoher durchlaufleistung |
CA2512144A CA2512144C (en) | 2003-01-13 | 2003-12-04 | Solid surface for biomolecule delivery and high-throughput assay |
US11/303,082 US20070269891A9 (en) | 2003-01-13 | 2005-12-14 | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells |
HK06109068.2A HK1088637A1 (en) | 2003-01-13 | 2006-08-15 | Solid surface for biomolecule delivery and high-throughput assay |
US11/526,927 US20070020761A1 (en) | 2003-01-13 | 2006-09-26 | Solid surface for biomolecule delivery and high-throughput assay |
US11/527,134 US8192989B2 (en) | 2003-01-13 | 2006-09-26 | Solid surface for biomolecule delivery and high-throughput assay |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/341,059 US20040138154A1 (en) | 2003-01-13 | 2003-01-13 | Solid surface for biomolecule delivery and high-throughput assay |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/303,082 Continuation-In-Part US20070269891A9 (en) | 2003-01-13 | 2005-12-14 | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells |
US11/527,134 Continuation US8192989B2 (en) | 2003-01-13 | 2006-09-26 | Solid surface for biomolecule delivery and high-throughput assay |
US11/526,927 Division US20070020761A1 (en) | 2003-01-13 | 2006-09-26 | Solid surface for biomolecule delivery and high-throughput assay |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040138154A1 true US20040138154A1 (en) | 2004-07-15 |
Family
ID=32711435
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/341,059 Abandoned US20040138154A1 (en) | 2003-01-13 | 2003-01-13 | Solid surface for biomolecule delivery and high-throughput assay |
US11/527,134 Expired - Fee Related US8192989B2 (en) | 2003-01-13 | 2006-09-26 | Solid surface for biomolecule delivery and high-throughput assay |
US11/526,927 Abandoned US20070020761A1 (en) | 2003-01-13 | 2006-09-26 | Solid surface for biomolecule delivery and high-throughput assay |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/527,134 Expired - Fee Related US8192989B2 (en) | 2003-01-13 | 2006-09-26 | Solid surface for biomolecule delivery and high-throughput assay |
US11/526,927 Abandoned US20070020761A1 (en) | 2003-01-13 | 2006-09-26 | Solid surface for biomolecule delivery and high-throughput assay |
Country Status (12)
Country | Link |
---|---|
US (3) | US20040138154A1 (ko) |
EP (2) | EP2253718B1 (ko) |
JP (1) | JP4580764B2 (ko) |
KR (1) | KR100863774B1 (ko) |
CN (1) | CN1738911B (ko) |
AT (1) | ATE477336T1 (ko) |
AU (1) | AU2003298863B2 (ko) |
CA (1) | CA2512144C (ko) |
DE (1) | DE60333793D1 (ko) |
DK (1) | DK2253718T3 (ko) |
HK (1) | HK1088637A1 (ko) |
WO (1) | WO2004065636A1 (ko) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006066001A2 (en) * | 2004-12-17 | 2006-06-22 | Nitto Denko Corporation | Immobilized degradable cationic polymer for transfecting eukaryotic cells |
US20060134790A1 (en) * | 2003-01-13 | 2006-06-22 | Yasunobu Tanaka | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells |
US20070020761A1 (en) * | 2003-01-13 | 2007-01-25 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
US20070243157A1 (en) * | 2006-04-06 | 2007-10-18 | Nitto Denko Corporation | Biodegradable cationic polymers |
US20080207553A1 (en) * | 2004-10-04 | 2008-08-28 | Nitto Denko Corporation | Biodegradable Cationic Polymers |
US20080312174A1 (en) * | 2007-06-05 | 2008-12-18 | Nitto Denko Corporation | Water soluble crosslinked polymers |
US20090105179A1 (en) * | 2007-09-14 | 2009-04-23 | Nitto Denko Corporation | Drug carriers |
US20100015232A1 (en) * | 2006-07-07 | 2010-01-21 | Aarhus Universitet | Nanoparticles for nucleic acid delivery |
US20100028416A1 (en) * | 2008-07-30 | 2010-02-04 | Nitto Denko Corporation | Drug carriers |
CN102010508A (zh) * | 2010-10-19 | 2011-04-13 | 北京大学 | 一种阳离子聚合物及其制备方法和应用 |
US20130210015A1 (en) * | 2012-02-13 | 2013-08-15 | Molecular Systems Corporation | System and method for processing and detecting nucleic acids |
US8574623B2 (en) | 2004-12-22 | 2013-11-05 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
US8652526B2 (en) | 2004-12-22 | 2014-02-18 | Nitto Denko Corporation | Drug carrier and drug carrier kit for inhibiting fibrosis |
US8686052B2 (en) | 2007-03-30 | 2014-04-01 | Nitto Denko Corporation | Targeting agent for cancer cell or cancer-associated fibroblast |
US9382532B2 (en) | 2012-10-25 | 2016-07-05 | Neumodx Molecular, Inc. | Method and materials for isolation of nucleic acid materials |
US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
US9604213B2 (en) | 2012-02-13 | 2017-03-28 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US9637775B2 (en) | 2012-02-13 | 2017-05-02 | Neumodx Molecular, Inc. | System and method for processing biological samples |
CN114867472A (zh) * | 2019-12-23 | 2022-08-05 | 巴斯克大学 | 用于基因治疗的金脂质纳米颗粒 |
US11485968B2 (en) | 2012-02-13 | 2022-11-01 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US11648561B2 (en) | 2012-02-13 | 2023-05-16 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
PT3645719T (pt) | 2017-06-30 | 2022-05-18 | Inscripta Inc | Métodos, módulos, instrumentos e sistemas automatizados de processamento de células |
US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
US10526598B2 (en) | 2018-04-24 | 2020-01-07 | Inscripta, Inc. | Methods for identifying T-cell receptor antigens |
CA3108767A1 (en) | 2018-06-30 | 2020-01-02 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
US10815467B2 (en) | 2019-03-25 | 2020-10-27 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
CA3139122C (en) | 2019-06-06 | 2023-04-25 | Inscripta, Inc. | Curing for recursive nucleic acid-guided cell editing |
US11203762B2 (en) | 2019-11-19 | 2021-12-21 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
CA3157127A1 (en) | 2019-12-18 | 2021-06-24 | Aamir MIR | Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells |
AU2021213705A1 (en) | 2020-01-27 | 2022-06-16 | Inscripta, Inc. | Electroporation modules and instrumentation |
US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
WO2022060749A1 (en) | 2020-09-15 | 2022-03-24 | Inscripta, Inc. | Crispr editing to embed nucleic acid landing pads into genomes of live cells |
US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
EP4271802A1 (en) | 2021-01-04 | 2023-11-08 | Inscripta, Inc. | Mad nucleases |
WO2022150269A1 (en) | 2021-01-07 | 2022-07-14 | Inscripta, Inc. | Mad nucleases |
US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5861306A (en) * | 1995-08-24 | 1999-01-19 | Millenium Biologix, Inc. | Multi-well bone culture device for use in assessment of bone cell activity |
US6025337A (en) * | 1994-06-27 | 2000-02-15 | Johns Hopkins University | Solid microparticles for gene delivery |
US6159591A (en) * | 1997-11-19 | 2000-12-12 | Amcol International Corporation | Multicomponent superabsorbent gel particles |
US6231960B1 (en) * | 1995-03-30 | 2001-05-15 | The Procter & Gamble Company | Biodegradable and/or compostable polymers made from conjugated dienes such as isoprene and 2,3-dimethyl-1,3-butadiene |
US6319516B1 (en) * | 1991-08-28 | 2001-11-20 | The University Of Tennessee Research Corporation | Acid salts of cholesterol |
US20020006664A1 (en) * | 1999-09-17 | 2002-01-17 | Sabatini David M. | Arrayed transfection method and uses related thereto |
US20020052443A1 (en) * | 1993-10-27 | 2002-05-02 | Greenwald Richard B | Non-antigenic branched polymer conjugates |
US20020146825A1 (en) * | 2000-11-03 | 2002-10-10 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
US6475994B2 (en) * | 1998-01-07 | 2002-11-05 | Donald A. Tomalia | Method and articles for transfection of genetic material |
US6544790B1 (en) * | 1999-09-17 | 2003-04-08 | Whitehead Institute For Biomedical Research | Reverse transfection method |
US20030099927A1 (en) * | 2000-01-24 | 2003-05-29 | Yingjian Wang | Arrays for bringing two or more reagents in contact with one or more biological targets and methods for making and using the arrays |
US6586524B2 (en) * | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US20040048260A1 (en) * | 2002-09-10 | 2004-03-11 | Fu-Hsiung Chang | Transfection of nucleic acid |
US20040120979A1 (en) * | 2000-06-02 | 2004-06-24 | Roessler Blake J. | Delivery systems comprising biocompatible and bioerodable membranes |
US20050176132A1 (en) * | 2004-02-10 | 2005-08-11 | Yasunobu Tanaka | Culture device and method for eukaryotic cell transfection |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
JP2001508815A (ja) | 1996-05-29 | 2001-07-03 | セル ジェネシス,インコーポレイテッド | カチオン性ポリマー/脂質核酸送達ビヒクル |
EP0920339A2 (en) * | 1996-07-09 | 1999-06-09 | The Johns Hopkins University | Gene delivery system |
DE19743135A1 (de) | 1997-09-30 | 1999-04-01 | Hoechst Marion Roussel De Gmbh | Biologisch verträgliche niedermolekular Polyethylenimine |
US6319715B1 (en) | 2000-04-21 | 2001-11-20 | Cornell Research Foundation, Inc. | Method of enhancing the delivery of nucleic acids using silica nanoparticles |
US20020009807A1 (en) | 2000-05-18 | 2002-01-24 | Lance Kam | Lipid bilayer array method and devices |
US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
CA2427916C (en) * | 2000-11-03 | 2012-01-17 | The Regents Of The University Of Michigan | Surface transfection and expression procedure |
US20040234586A1 (en) * | 2001-06-11 | 2004-11-25 | Sylvain Meloche | Compositions and methods for enhancing nucleic acid transfer into cells |
US20040138154A1 (en) * | 2003-01-13 | 2004-07-15 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
-
2003
- 2003-01-13 US US10/341,059 patent/US20040138154A1/en not_active Abandoned
- 2003-12-04 EP EP10075260A patent/EP2253718B1/en not_active Expired - Lifetime
- 2003-12-04 CN CN2003801086781A patent/CN1738911B/zh not_active Expired - Fee Related
- 2003-12-04 KR KR1020057012842A patent/KR100863774B1/ko not_active IP Right Cessation
- 2003-12-04 WO PCT/US2003/038498 patent/WO2004065636A1/en active Application Filing
- 2003-12-04 AT AT03796622T patent/ATE477336T1/de not_active IP Right Cessation
- 2003-12-04 DK DK10075260.9T patent/DK2253718T3/da active
- 2003-12-04 DE DE60333793T patent/DE60333793D1/de not_active Expired - Lifetime
- 2003-12-04 JP JP2004566927A patent/JP4580764B2/ja not_active Expired - Fee Related
- 2003-12-04 CA CA2512144A patent/CA2512144C/en not_active Expired - Fee Related
- 2003-12-04 EP EP03796622A patent/EP1587954B1/en not_active Expired - Lifetime
- 2003-12-04 AU AU2003298863A patent/AU2003298863B2/en not_active Ceased
-
2006
- 2006-08-15 HK HK06109068.2A patent/HK1088637A1/xx not_active IP Right Cessation
- 2006-09-26 US US11/527,134 patent/US8192989B2/en not_active Expired - Fee Related
- 2006-09-26 US US11/526,927 patent/US20070020761A1/en not_active Abandoned
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US6319516B1 (en) * | 1991-08-28 | 2001-11-20 | The University Of Tennessee Research Corporation | Acid salts of cholesterol |
US20020052443A1 (en) * | 1993-10-27 | 2002-05-02 | Greenwald Richard B | Non-antigenic branched polymer conjugates |
US6025337A (en) * | 1994-06-27 | 2000-02-15 | Johns Hopkins University | Solid microparticles for gene delivery |
US6231960B1 (en) * | 1995-03-30 | 2001-05-15 | The Procter & Gamble Company | Biodegradable and/or compostable polymers made from conjugated dienes such as isoprene and 2,3-dimethyl-1,3-butadiene |
US5861306A (en) * | 1995-08-24 | 1999-01-19 | Millenium Biologix, Inc. | Multi-well bone culture device for use in assessment of bone cell activity |
US6159591A (en) * | 1997-11-19 | 2000-12-12 | Amcol International Corporation | Multicomponent superabsorbent gel particles |
US6475994B2 (en) * | 1998-01-07 | 2002-11-05 | Donald A. Tomalia | Method and articles for transfection of genetic material |
US20020006664A1 (en) * | 1999-09-17 | 2002-01-17 | Sabatini David M. | Arrayed transfection method and uses related thereto |
US6544790B1 (en) * | 1999-09-17 | 2003-04-08 | Whitehead Institute For Biomedical Research | Reverse transfection method |
US20030099927A1 (en) * | 2000-01-24 | 2003-05-29 | Yingjian Wang | Arrays for bringing two or more reagents in contact with one or more biological targets and methods for making and using the arrays |
US20040120979A1 (en) * | 2000-06-02 | 2004-06-24 | Roessler Blake J. | Delivery systems comprising biocompatible and bioerodable membranes |
US20020146825A1 (en) * | 2000-11-03 | 2002-10-10 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
US6586524B2 (en) * | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US20040048260A1 (en) * | 2002-09-10 | 2004-03-11 | Fu-Hsiung Chang | Transfection of nucleic acid |
US20050176132A1 (en) * | 2004-02-10 | 2005-08-11 | Yasunobu Tanaka | Culture device and method for eukaryotic cell transfection |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060134790A1 (en) * | 2003-01-13 | 2006-06-22 | Yasunobu Tanaka | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells |
US20070020761A1 (en) * | 2003-01-13 | 2007-01-25 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
US20070072171A1 (en) * | 2003-01-13 | 2007-03-29 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
US20070269891A9 (en) * | 2003-01-13 | 2007-11-22 | Yasunobu Tanaka | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells |
US8192989B2 (en) | 2003-01-13 | 2012-06-05 | Nitto Denko Corporation | Solid surface for biomolecule delivery and high-throughput assay |
US7700542B2 (en) | 2004-10-04 | 2010-04-20 | Nitto Denko Corporation | Biodegradable cationic polymers |
US8258235B2 (en) | 2004-10-04 | 2012-09-04 | Nitto Denko Corporation | Biodegradable cationic polymers |
US20080207553A1 (en) * | 2004-10-04 | 2008-08-28 | Nitto Denko Corporation | Biodegradable Cationic Polymers |
US20100210715A1 (en) * | 2004-10-04 | 2010-08-19 | Nitto Denko Corporation | Biodegradable cationic polymers |
WO2006066001A3 (en) * | 2004-12-17 | 2006-09-08 | Nitto Denko Corp | Immobilized degradable cationic polymer for transfecting eukaryotic cells |
WO2006066001A2 (en) * | 2004-12-17 | 2006-06-22 | Nitto Denko Corporation | Immobilized degradable cationic polymer for transfecting eukaryotic cells |
US8652526B2 (en) | 2004-12-22 | 2014-02-18 | Nitto Denko Corporation | Drug carrier and drug carrier kit for inhibiting fibrosis |
US8574623B2 (en) | 2004-12-22 | 2013-11-05 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
US7700541B2 (en) | 2006-04-06 | 2010-04-20 | Nitto Denko Corporation | Biodegradable cationic polymers |
US20070243157A1 (en) * | 2006-04-06 | 2007-10-18 | Nitto Denko Corporation | Biodegradable cationic polymers |
US20100015232A1 (en) * | 2006-07-07 | 2010-01-21 | Aarhus Universitet | Nanoparticles for nucleic acid delivery |
US8686052B2 (en) | 2007-03-30 | 2014-04-01 | Nitto Denko Corporation | Targeting agent for cancer cell or cancer-associated fibroblast |
US20080312174A1 (en) * | 2007-06-05 | 2008-12-18 | Nitto Denko Corporation | Water soluble crosslinked polymers |
US8003621B2 (en) | 2007-09-14 | 2011-08-23 | Nitto Denko Corporation | Drug carriers |
US20090105179A1 (en) * | 2007-09-14 | 2009-04-23 | Nitto Denko Corporation | Drug carriers |
US20100028416A1 (en) * | 2008-07-30 | 2010-02-04 | Nitto Denko Corporation | Drug carriers |
CN102010508A (zh) * | 2010-10-19 | 2011-04-13 | 北京大学 | 一种阳离子聚合物及其制备方法和应用 |
US9339812B2 (en) * | 2012-02-13 | 2016-05-17 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US11485968B2 (en) | 2012-02-13 | 2022-11-01 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US11931740B2 (en) | 2012-02-13 | 2024-03-19 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US9403165B2 (en) | 2012-02-13 | 2016-08-02 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US9433940B2 (en) | 2012-02-13 | 2016-09-06 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US9441219B2 (en) | 2012-02-13 | 2016-09-13 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US9452430B1 (en) | 2012-02-13 | 2016-09-27 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US11717829B2 (en) | 2012-02-13 | 2023-08-08 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US20130210015A1 (en) * | 2012-02-13 | 2013-08-15 | Molecular Systems Corporation | System and method for processing and detecting nucleic acids |
US9604213B2 (en) | 2012-02-13 | 2017-03-28 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US9637775B2 (en) | 2012-02-13 | 2017-05-02 | Neumodx Molecular, Inc. | System and method for processing biological samples |
US9738887B2 (en) | 2012-02-13 | 2017-08-22 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US10010888B2 (en) | 2012-02-13 | 2018-07-03 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US10041062B2 (en) | 2012-02-13 | 2018-08-07 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US10093963B2 (en) | 2012-02-13 | 2018-10-09 | Neumodx Molecular, Inc. | System and method for processing biological samples |
US10557132B2 (en) | 2012-02-13 | 2020-02-11 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US11708597B2 (en) | 2012-02-13 | 2023-07-25 | Neumodx Molecular, Inc. | Pin-based valve actuation system for processing biological samples |
US11142757B2 (en) | 2012-02-13 | 2021-10-12 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US11655467B2 (en) | 2012-02-13 | 2023-05-23 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US9101930B2 (en) | 2012-02-13 | 2015-08-11 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US11648561B2 (en) | 2012-02-13 | 2023-05-16 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US10633647B2 (en) | 2012-10-25 | 2020-04-28 | Neumodx Molecular, Inc. | Method and materials for isolation of nucleic acid materials |
US9540636B2 (en) | 2012-10-25 | 2017-01-10 | Neumodx Molecular, Inc. | Method and materials for isolation of nucleic acid materials |
US9382532B2 (en) | 2012-10-25 | 2016-07-05 | Neumodx Molecular, Inc. | Method and materials for isolation of nucleic acid materials |
CN114867472A (zh) * | 2019-12-23 | 2022-08-05 | 巴斯克大学 | 用于基因治疗的金脂质纳米颗粒 |
Also Published As
Publication number | Publication date |
---|---|
KR20050096130A (ko) | 2005-10-05 |
EP1587954A1 (en) | 2005-10-26 |
JP2006513703A (ja) | 2006-04-27 |
AU2003298863B2 (en) | 2008-04-24 |
US8192989B2 (en) | 2012-06-05 |
DE60333793D1 (de) | 2010-09-23 |
ATE477336T1 (de) | 2010-08-15 |
DK2253718T3 (da) | 2012-10-08 |
HK1088637A1 (en) | 2006-11-10 |
WO2004065636A1 (en) | 2004-08-05 |
CN1738911A (zh) | 2006-02-22 |
US20070072171A1 (en) | 2007-03-29 |
EP2253718A3 (en) | 2010-12-15 |
CN1738911B (zh) | 2012-09-05 |
CA2512144C (en) | 2013-07-02 |
EP1587954A4 (en) | 2006-04-12 |
AU2003298863A1 (en) | 2004-08-13 |
EP2253718A2 (en) | 2010-11-24 |
CA2512144A1 (en) | 2004-08-05 |
EP1587954B1 (en) | 2010-08-11 |
EP2253718B1 (en) | 2012-07-04 |
KR100863774B1 (ko) | 2008-10-16 |
JP4580764B2 (ja) | 2010-11-17 |
US20070020761A1 (en) | 2007-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8192989B2 (en) | Solid surface for biomolecule delivery and high-throughput assay | |
KR101263173B1 (ko) | 진핵 세포의 트랜스펙션을 위한 고정화된 분해가능한양이온성 중합체 | |
US20060134790A1 (en) | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells | |
US7358223B2 (en) | Biodegradable cationic polymers | |
US20080312174A1 (en) | Water soluble crosslinked polymers | |
US7125709B2 (en) | Culture device and method for eukaryotic cell transfection | |
EP1723240B1 (en) | Culture device and method for eukaryotic cell transfection | |
Schlaeger et al. | Transient transfection in mammalian cells: a basic study for an efficient and cost-effective scale up process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NITTO DENKO CORPORATION, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YU, LEI;MATSUMOTO, KENJI;JI, SHOUPING;AND OTHERS;REEL/FRAME:013975/0118;SIGNING DATES FROM 20030325 TO 20030411 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |